Was haben wir aus der deutschen COPD-Kohorte COSYCONET gelernt und wie geht es weiter?
暂无分享,去创建一个
C. Vogelmeier | K. Rabe | H. Watz | T. Welte | R. Bals | H. Kauczor | F. Herth | P. Alter | R. Jörres | F. Trudzinski | C. Fischer | K. Kahnert | J. Behr | Sandra Söhler | Inge Kokot
[1] H. Watz,et al. Association of coronary artery calcification with clinical and physiological characteristics in patients with COPD: Results from COSYCONET. , 2022, Respiratory medicine.
[2] R. Holle,et al. Basic Determinants of Disease Knowledge in COPD Patients: Results from COSYCONET , 2022, Patient preference and adherence.
[3] Claus F. Vogelmeier,et al. Differences in the Measurement of Functional Residual Capacity Between Body Plethysmographs of Two Manufacturers , 2022, International journal of chronic obstructive pulmonary disease.
[4] C. Kropf-Sanchen,et al. Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease: results from COSYCONET , 2022, Scientific reports.
[5] C. Kropf-Sanchen,et al. Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment , 2022, Scientific reports.
[6] H. Watz,et al. IgE is associated with exacerbations and lung function decline in COPD , 2022, Respiratory Research.
[7] H. Watz,et al. Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET , 2021, International journal of chronic obstructive pulmonary disease.
[8] Bertram J Jobst,et al. Quantification of pulmonary perfusion abnormalities using DCE-MRI in COPD: comparison with quantitative CT and pulmonary function , 2021, European Radiology.
[9] F. Herth,et al. Oxygenated Hemoglobin Predicts Outcome in Patients with Chronic Lung Allograft Dysfunction , 2021, Respiration.
[10] Bertram J Jobst,et al. Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET , 2021, Respiratory Research.
[11] H. Kauczor,et al. Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities , 2021, Clinical Research in Cardiology.
[12] P. Boor,et al. Measurement of urinary Dickkopf-3 uncovered silent progressive kidney injury in patients with chronic obstructive pulmonary disease. , 2021, Kidney international.
[13] H. Kauczor,et al. Impact of the COVID-19 pandemic on the behaviour and health status of patients with COPD: results from the German COPD cohort COSYCONET , 2021, ERJ Open Research.
[14] H. Watz,et al. COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort. , 2021, Respiratory medicine.
[15] H. Kauczor,et al. Echo Time‐Dependent Observed Lung T1 in Patients With Chronic Obstructive Pulmonary Disease in Correlation With Quantitative Imaging and Clinical Indices , 2021, Journal of magnetic resonance imaging : JMRI.
[16] R. Holle,et al. Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences , 2021, International journal of chronic obstructive pulmonary disease.
[17] H. Watz,et al. Prognostic Value of Oxygenated Hemoglobin Assessed during Acute Exacerbations of Chronic Pulmonary Disease , 2021, Respiration.
[18] R. Holle,et al. Deterioration and Mortality Risk of COPD Patients Not Fitting into Standard GOLD Categories: Results of the COSYCONET Cohort , 2021, Respiration.
[19] R. Holle,et al. Impact of Education on COPD Severity and All-Cause Mortality in Lifetime Never-Smokers and Longtime Ex-Smokers: Results of the COSYCONET Cohort , 2020, International journal of chronic obstructive pulmonary disease.
[20] R. Holle,et al. Utilization and determinants of use of non-pharmacological interventions in COPD: Results of the COSYCONET cohort. , 2020, Respiratory medicine.
[21] H. Kauczor,et al. Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET. , 2020, Respiratory medicine.
[22] H. Watz,et al. Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET , 2020, ERJ Open Research.
[23] H. Kauczor,et al. Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET , 2020, Scientific Reports.
[24] P. Dorinsky,et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.
[25] R. Holle,et al. Health-related quality of life associates with change in FEV1 in COPD: results from the COSYCONET cohort , 2020, BMC Pulmonary Medicine.
[26] C. Vogelmeier,et al. The impact of COPD on polyneuropathy: results from the German COPD cohort COSYCONET , 2020, Pneumologie.
[27] S. Blankenberg,et al. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study , 2019, European Respiratory Journal.
[28] T. Brinker,et al. Time-updated resting heart rate predicts mortality in patients with COPD , 2019, Clinical Research in Cardiology.
[29] C. Kropf-Sanchen,et al. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort , 2019, Respiratory Research.
[30] H. Kauczor,et al. CAT score single item analysis in patients with COPD: results from COSYCONET , 2019, Pneumologie.
[31] H. Watz,et al. Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort , 2019, Patient preference and adherence.
[32] Hans-Peter Lenhof,et al. Low miR-150-5p and miR-320b Expression Predicts Reduced Survival of COPD Patients , 2019, Cells.
[33] H. Watz,et al. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort , 2019, International journal of chronic obstructive pulmonary disease.
[34] H. Watz,et al. Consequences of chronic kidney disease in chronic obstructive pulmonary disease , 2019, Respiratory Research.
[35] R. Holle,et al. Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET , 2019, International journal of chronic obstructive pulmonary disease.
[36] H. Kauczor,et al. Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort. , 2019, Respiratory medicine.
[37] H. Watz,et al. Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD , 2019, Respiratory Research.
[38] H. Watz,et al. Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study , 2019, Respiratory Research.
[39] Bertram J Jobst,et al. Comparison of quantitative regional perfusion‐weighted phase resolved functional lung (PREFUL) MRI with dynamic gadolinium‐enhanced regional pulmonary perfusion MRI in COPD patients , 2018, Journal of magnetic resonance imaging : JMRI.
[40] C. Vogelmeier,et al. Medical Treatment of COPD. , 2018, Deutsches Arzteblatt international.
[41] H. Watz,et al. Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort , 2018, International journal of chronic obstructive pulmonary disease.
[42] K. Rabe,et al. Influence of body mass on predicted values of static hyperinflation in COPD , 2018, International journal of chronic obstructive pulmonary disease.
[43] H. Kauczor,et al. Design and application of an MR reference phantom for multicentre lung imaging trials , 2018, PloS one.
[44] H. Watz,et al. Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach , 2018, Respiratory Research.
[45] Christina Backes,et al. Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development , 2018, Genom. Proteom. Bioinform..
[46] H. Watz,et al. Left ventricular volume and wall stress are linked to lung function impairment in COPD. , 2017, International journal of cardiology.
[47] P. Grenier,et al. Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans , 2018, Chronic respiratory disease.
[48] J. Hohlfeld,et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. , 2018, The Lancet. Respiratory medicine.
[49] H. Watz,et al. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. , 2018, Respiratory medicine.
[50] R. Holle,et al. Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD. , 2018, Pulmonary pharmacology & therapeutics.
[51] J. Vestbo,et al. The revised GOLD 2017 COPD categorization in relation to comorbidities , 2018, Pneumologie.
[52] R. Holle,et al. The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort , 2017, International journal of chronic obstructive pulmonary disease.
[53] Sally J. Singh,et al. Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease. , 2017, Journal of the American Medical Directors Association.
[54] H. Kauczor,et al. Cardiovascular risk in patients with alpha-1-antitrypsin deficiency , 2017, Respiratory Research.
[55] R. Holle,et al. Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort , 2017, PloS one.
[56] R. Holle,et al. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients , 2017, Respiratory Research.
[57] R. Holle,et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences‐Comorbidities Network Study , 2017, American journal of respiratory and critical care medicine.
[58] R. Holle,et al. Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort , 2017, Respiratory Research.
[59] R. Holle,et al. Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies – A Novel Stepwise Approach by Evaluation of Medication , 2016, PloS one.
[60] R. Holle,et al. Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies , 2016, Respiratory Research.
[61] R. Holle,et al. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities , 2016, BMC Pulmonary Medicine.
[62] R. Holle,et al. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. , 2016, Respiratory medicine.
[63] S. Petersen,et al. Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. , 2016, American journal of respiratory and critical care medicine.
[64] R. Holle,et al. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. , 2016, Respiratory medicine.
[65] Joyce D. Schroeder,et al. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus , 2014, BMC Pulmonary Medicine.
[66] B. Celli,et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.
[67] W. Rief,et al. Mental disorders and quality of life in COPD patients and their spouses , 2008, International journal of chronic obstructive pulmonary disease.
[68] I. Kopp,et al. Die Nationale VersorgungsLeitlinie COPD , 2007, Medizinische Klinik.
[69] C. Vogelmeier,et al. [Systemic manifestations and comorbidities in patients with chronic obstructive pulmonary disease (COPD) and their effect on clinical state and course of the disease--an overview of the cohort study COSYCONET]. , 2010, Deutsche medizinische Wochenschrift.
[70] G. Ollenschläger,et al. [The German Program for Disease Management Guidelines: COPD Guideline 2006. Short review]. , 2006, Medizinische Klinik.